Categories
Blood Cancer

BELINDA: Tisagenlecleucel in B-cell NHL [Video]

Michael Bishop, MD, University of Chicago, Chicago, IL, discusses results from the Phase III BELINDA trial (NCT03570892), which assessed tisagenlecleucel (tisa-cel), a chimeric antigen receptor (CAR) T-cell therapy, in patients with aggressive B-cell non-Hodgkin lymphoma. The primary endpoint, which was event-free survival, was not met, and tisa-cel was not superior to the current standard of care. Dr Bishop highlights the time taken for the therapy to be administered, bridging therapy, and the dosage of lymphodepleting chemotherapy to be factors affecting the trial results. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

The role of CAR-T therapy in hematologic malignancies [Video]

Michael Bishop, MD, University of Chicago, Chicago, IL, describes advances in chimeric antigen receptor (CAR) T-cell therapy for hematologic malignancies. Data from the JULIET (NCT02445248), TRANSFORM (NCT03575351), BELINDA (NCT03570892), ZUMA-1 (NCT02348216), and ZUMA-7 (NCT03391466) trials have demonstrated CAR T-cell therapy as a promising frontline therapy in non-Hodgkin lymphoma. Dr Bishop additionally highlights updates in multiple myeloma and acute lymphoblastic leukemia (ALL), as well as strategies to manage CAR T-cell toxicity. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

Treating TP53 mutant mantle cell lymphoma in the BOVen trial [Video]

Patients with TP53 mutant mantle cell lymphoma (MCL) represent an unmet need and there care no current frontline standard of care for these high risk patients. Anita Kumar, MD, Memorial Sloan Kettering, Short Hills, NJ, presents results from the Phase II BOVen trial (NCT03824483), which investigated zanubrutinib, obinutuzumab, and venetoclax in patients with TP53 mutant MCL. Two cycles of zanubrutinib and obinutuzumab were initially administered, followed by venetoclax. The regimen was well tolerated and displayed preliminary efficacy, with a majority of patients being in ongoing remission. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

The value of MRD assessment in lymphoma [Video]

Anita Kumar, MD, Memorial Sloan Kettering, Short Hills, NJ, describes the significance of monitoring minimal residual disease (MRD) in lymphoma. MRD detection can enable accurate evaluation of treatment response and help guide patients to the right treatment path. In the case of the Phase II BOVen trial (NCT03824483), which investigated zanubrutinib, obinutuzumab, and venetoclax in patients with TP53 mutant mantle cell lymphoma (MCL), patients who were MRD positive continued treatment. Dr Kumar additionally highlights the need for more research to evaluate the role of MRD in diffuse large B-cell lymphoma (DLBCL) surveillance. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

PD-1 blockade in Hodgkin lymphoma: moving up the ranks [Video]

Enhanced PD-1 signaling observed in classical Hodgkin lymphoma (cHL) and primary mediastinal large B-cell lymphoma (PMBL) led to the evaluation of PD-1 blockade as a new treatment option. Patients with cHL and PMBL have since shown some of the highest response rate to this approach, enabling substantial progress over the last decade. Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MI, talks on how the use of PD-1 blockade has developed over time, making its way from relapsed/refractory settings to frontline treatment. Studies have shown the addition of PD-1 blockade to standard treatments to improve outcomes in every circumstance and thus, these approaches are now being investigated in randomized clinical trials for frontline treatment and at first relapse. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

Addressing treating disparities in lymphoma treatment [Video]

Francine Foss, MD, Yale University School of Medicine, New Haven, CT, talks on potential disparities in lymphoma treatment and outcomes, especially in African-American patients with cutaneous T-cell lymphoma (CTCL), who may be perceived to have inferior outcomes. An analysis of patients across various centers will elucidate any potential associations between certain patient populations and treatment outcomes. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

Will CAR-T therapy take over from autologous transplantation in lymphoma? [Video]

Is there still a role for autologous stem cell transplantation in lymphoma? Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MI, shares his thoughts on this pertinent subject. With the emergence of highly active novel therapies, the use of autologous transplantation has come into question. Several studies have directly compared the use of CAR-T therapy versus transplantation, with mixed results. Further investigations are needed to determine if there are select populations who may benefit more from one approach or the other. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

MRD monitoring in CLL [Video]

Robin Foà, MD, Sapienza University of Rome, Rome, Italy, discusses the use of measurable residual disease (MRD) monitoring in chronic lymphocytic leukemia (CLL), comparing it to its role in indolent non-Hodgkin lymphoma (NHL). In recent years, new treatment modalities have enabled a large number of patients with CLL to achieve MRD negativity. Despite its common use in clinical trials, MRD negativity is currently not used in daily clinical practice, nor as a treatment endpoint in CLL in contrast to other hematological malignancies. With a majority of patients with CLL initiating therapy at an older age, MRD monitoring has not yet been implemented in clinical practice. Prof. Foà additionally discusses the relevance of chemoimmunotherapy in the context of new effective therapies for CLL. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

The role of MRD in the management of indolent NHL [Video]

Robin Foà, MD, Sapienza University of Rome, Rome, Italy, gives an overview of his talk on the clinical value of measurable residual disease (MRD) in indolent non-Hodgkin lymphoma (NHL), with a focus on follicular lymphoma (FL). Prof. Foà discusses the role of MRD monitoring in stratifying patients into different risk categories at diagnosis, as well as in refining the degree of clinical response to treatment and in predicting progression-free survival (PFS). In addition, the value of MRD in molecular testing and in helping treatment choice will also be examined. Despite its wide use in clinical trials and a large body of evidence demonstrating the benefits of MRD monitoring, it has not yet been implemented in clinical practice. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.